XTX Topco Ltd Invests $237,000 in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

XTX Topco Ltd purchased a new stake in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 43,740 shares of the company's stock, valued at approximately $237,000. XTX Topco Ltd owned about 0.06% of Eyepoint Pharmaceuticals at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Summit Investment Advisors Inc. lifted its stake in shares of Eyepoint Pharmaceuticals by 39.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock valued at $51,000 after purchasing an additional 1,940 shares during the period. GAMMA Investing LLC increased its position in Eyepoint Pharmaceuticals by 3,174.4% in the 1st quarter. GAMMA Investing LLC now owns 10,249 shares of the company's stock valued at $56,000 after buying an additional 9,936 shares in the last quarter. Virtus ETF Advisers LLC acquired a new position in Eyepoint Pharmaceuticals during the 4th quarter worth approximately $67,000. Raymond James Financial Inc. acquired a new position in Eyepoint Pharmaceuticals during the 4th quarter worth approximately $76,000. Finally, Arizona State Retirement System grew its stake in Eyepoint Pharmaceuticals by 12.7% in the first quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock valued at $90,000 after acquiring an additional 1,877 shares during the period. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Eyepoint Pharmaceuticals Stock Up 2.2%

EYPT stock traded up $0.24 during trading on Friday, reaching $11.09. The stock had a trading volume of 801,214 shares, compared to its average volume of 639,578. Eyepoint Pharmaceuticals, Inc. has a one year low of $3.91 and a one year high of $13.98. The company's 50 day moving average is $9.91 and its two-hundred day moving average is $7.54. The company has a market capitalization of $764.43 million, a price-to-earnings ratio of -4.14 and a beta of 1.73.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.18). The business had revenue of $5.33 million during the quarter, compared to the consensus estimate of $6.82 million. Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. As a group, research analysts predict that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on EYPT. Chardan Capital reaffirmed a "buy" rating and set a $27.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. Mizuho lowered their price objective on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a report on Friday, May 16th. HC Wainwright lifted their price objective on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Finally, Royal Bank Of Canada assumed coverage on shares of Eyepoint Pharmaceuticals in a report on Tuesday, June 17th. They issued an "outperform" rating and a $28.00 target price on the stock. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Eyepoint Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $25.38.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.